store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Oprozomib (PR-047) (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 58.00 | |
5 mg | In stock | $ 129.00 | |
10 mg | In stock | $ 173.00 | |
25 mg | In stock | $ 312.00 | |
50 mg | In stock | $ 468.00 | |
100 mg | In stock | $ 657.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 148.00 |
Description | Oprozomib (PR-047) (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity. |
Targets&IC50 | 20S proteasome β5:36 nM, 20S proteasome LMP7:82 nM |
In vitro | In various human tumor xenografts and mouse syngeneic models, Oprozomib can inhibit over 80% of proteasomes, inducing an anti-tumor response. Following repeated oral administration, Oprozomib demonstrates good safety and tolerability across most tissues in animals. |
In vivo | Oprozomib exhibits anti-MM (multiple myeloma) activity by inhibiting the migration and angiogenesis of MM cells. Furthermore, Oprozomib suppresses the activation of caspase-8, caspase-9, caspase-3, and PARP. |
Kinase Assay | ELISA-based active site binding assay: Samples (lysed cells or tissue homogenates) are treated for 1 h at room temperature with the biotinylated active site probe PR-584 (5-15 μM). Samples are denatured by addition of SDS (0.9% final) and heating to 100 °C for 5 min. The denatured samples are transferred to a 96-well or 384-well filter plat, mixed with streptavidin-sepharose beads (2.5-5 μL packed beads/well), and incubated for 1 h at room temperature on a plate shaker. The beads are washed 5 times with 100-200 μL /well of ELISA buffer (PBS, 1% bovine serum albumin, 0.1% Tween-20) by vacuum filtration. The beads are incubated overnight at 4 °C on a plate shaker with the following antibodies recognizing the six catalytic subunits diluted into ELISA buffer: β5, β1, and β2 diluted 1:3000, LMP7 and LMP2 diluted 1:5000, and MECL-1 diluted 1:1000. The beads are washed 5 times with 100-200 μL /well of ELISA buffer and incubated with HRP-conjugated secondary antibody diluted 1:5000 in ELISA buffer and incubated 2 h at room temperature on a plate shaker. The beads are washed 5 times with 100-200 μL /well of ELISA buffer and developed for chemiluminsecence signal using the supersignal ELISA pico substrate following the manufacturer's instructions. Luminescence is measured on a plate reader and converted to ng of proteasome or μg/ml of lysate by comparison with 20S proteasome or untreated cell lysate standard curves. For proteasome inhibitor studies, active site probe binding values are expressed as the percent of binding relative to DMSO treated cells. |
Cell Research | MTT assay(Only for Reference) |
Synonyms | PR-047, ONX 0912 |
Molecular Weight | 532.61 |
Formula | C25H32N4O7S |
CAS No. | 935888-69-0 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (174.6 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Oprozomib 935888-69-0 Autophagy Proteases/Proteasome Ubiquitination Proteasome apoptosis inhibit bioavailable immunoproteasome LMP7 PR-047 PR047 PR 047 orally ONX0912 ONX-0912 Inhibitor epoxyketone ONX 0912 inhibitor